Fundraising Fox

NeuroBo Pharmaceuticals

NASDAQ: MTVA

Cambridge, US · Founded 2014 · Delaware corporation · 3 known investors

Biotech

Founders & leadership

NeuroBo Pharmaceuticals was founded in 2014 by Mina Sooch.

MS
Mina SoochFounder
MH
Marshall H. WoodworthExecutive
HH
Hyung Heon KimExecutive
MM
Margaret McShaneExecutive
DL
David LowenschussExecutive
CB
Charles BisgaierNamed on SEC filing
DO
Daniela OniciuNamed on SEC filing

Board

PK
P. Kent HawrylukBoard of Directors Member
AZ
Amy Zaremba RabournBoard director
SH
Stephen HaakensonBoard of Directors Member
DG
D. Gordon StricklandBoard director
JP
James P. TursiBoard director

Investors · 3

Excel Venture ManagementreportedBoston · $1M – $5Mvia Steve Gullans · board
GREAT LAKES BAY VENTUREreportedSaginaw

Also in the syndicate · 1

Dong-A ST Co., Ltd.

Reported raises · per SEC filings

Form D private placements

$98.9M disclosed across 9 rounds · 2014–2025

▶$10MraisedMay 2025 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark A. GlickmanDirector
  • Andrew KovenDirector
  • Jason L. GrovesDirector
  • Marshall H. WoodworthExecutive Officer
  • D. Gordon StricklandDirector
  • Michael SalsburyDirector
  • James P. TursiDirector
  • Hyung Heon KimExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
Sales commissions
$422.7K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17MraisedJul 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • D. Gordon StricklandDirector
  • James P. TursiDirector
  • Michael SalsburyDirector
  • Jason L. GrovesDirector
  • Mark A. GlickmanDirector
  • Andrew KovenDirector
  • Marshall H. WoodworthExecutive Officer
  • Hyung Heon KimExecutive Officer, Director
Offering amount
$17M
Amount sold
$17M
Sales commissions
$489.9K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14MraisedOct 2021 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jason GrovesDirector
  • Akash BakshiExecutive Officer
  • Hyung Heon KimDirector
  • Na Yeon KimDirector
  • Andrew I KovenDirector
  • Douglas J. SwirskyDirector
  • Richard J. KangExecutive Officer, Director
  • Michael SalsburyDirector
Offering amount
$14M
Amount sold
$14M
Sales commissions
$1.1M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedFeb 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeong Gyun OhDirector
  • Douglas SwirskyDirector
  • Jason GrovesDirector
  • Na Yeon KimDirector
  • Nicola ShannonExecutive Officer
  • Akash BakshiExecutive Officer, Director
  • Richard J. KangExecutive Officer, Director
  • Michael SalsburyDirector
Offering amount
$10M
Amount sold
$10M
Sales commissions
$700K
Placement agents
H.C. Wainwright & Co., Inc.
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17MraisedJan 2021 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard J. KangExecutive Officer, Director
  • Akash BakshiExecutive Officer, Director
  • Andrew BartynskiExecutive Officer
  • Nadja MannowetzExecutive Officer
  • Douglas SwirskyDirector
  • Na Yeon KimDirector
  • Jason GrovesDirector
  • Jeong Gyun OhDirector
  • Michael SalsburyDirector
  • Nicola ShannonExecutive Officer
Offering amount
$17M
Amount sold
$17M
Finders' fees
$64K
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.5MraisedMar 2017 · 26 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey MathiesenExecutive Officer
  • P. Kent HawrylukDirector
  • Andy SassineDirector
  • Steve GullansDirector
  • Lee S. GoldenExecutive Officer
  • Mina SoochExecutive Officer, Director
  • Charles BisgaierExecutive Officer, Director
  • Pedro LichtingerDirector
  • Kenneth KouskyDirector
  • Seth RenoExecutive Officer
Offering amount
$12.5M
Amount sold
$12.5M
Sales commissions
$1M
Placement agents
Piper Jaffray & Co., LifeSci Capital LLC
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.6MraisedApr 2016 · 59 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey MathiesenExecutive Officer
  • Mina SoochExecutive Officer, Director
  • Charles BisgaierExecutive Officer, Director
  • Daniela OniciuExecutive Officer
  • Margaret McShaneExecutive Officer
  • Seth RenoExecutive Officer
  • Andy SassineDirector
  • Steve GullansDirector
  • David LowenschussExecutive Officer
  • Pedro LichtingerDirector
  • Kenneth KouskyDirector
  • P. Kent HawrylukDirector
Offering amount
$14M
Amount sold
$10.6M
Minimum investment
$10K
Proceeds to insiders
$900K
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedApr 2015 · 46 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kenneth KouskyDirector
  • David LowenschussExecutive Officer
  • Daniela OniciuExecutive Officer
  • Charles BisgaierExecutive Officer
  • Mina SoochExecutive Officer
  • P. Kent HawrylukDirector
  • Margaret McShaneExecutive Officer
  • Amy Zaremba RabournDirector
Offering amount
$5M
Amount sold
$5M
Minimum investment
$10K
Proceeds to insiders
$686.9K
First sale
Mar 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

NeuroBo Pharmaceuticals Reveals Promising Therapeutic Developments | Nasdaqnasdaq.com · Nov 2024We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Ratefinance.yahoo.com · Sep 2024NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | NRBO Stock Newsstocktitan.net · Jun 2024NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd. | MarketScreenermarketscreener.com · Jun 2024

Frequently asked questions

Who founded NeuroBo Pharmaceuticals?
NeuroBo Pharmaceuticals was founded by Mina Sooch in 2014.
Who are NeuroBo Pharmaceuticals's investors?
NeuroBo Pharmaceuticals's investors include Excel Venture Management, GREAT LAKES BAY VENTURE.
How much funding has NeuroBo Pharmaceuticals raised?
NeuroBo Pharmaceuticals has disclosed $98.9M raised across 9 rounds.
Where is NeuroBo Pharmaceuticals headquartered?
NeuroBo Pharmaceuticals is headquartered in Cambridge, US.